Deqi Pharma's new class of drugs for the treatment of HCC, ATG-008, gets clinical approval

June 2018, DeqiPharmaceutical(announced that theCompany(developed for the treatment of advanced hepatocellular carcinoma (HCC) of a class ofnew drugs(through the NationalMedicines(The Regulatory Authority's new drug research application review), successfully obtained clinical approvalabout ATG-008
ATG-008 is China's first new generation of TORC1/TORC2 kinase dual-target inhibitors acting on the mTOR pathway, as a "special approval process" focused on supporting the country's 1 new drug, this successful approval, fully reflects the national anti-tumor innovationdrug(support)ATG-008 is the first innovative drug in the Asia Pacific region to be approved for clinicaltrials (the first innovative drug in the world) and the first drug of its kind in the world to enter clinical trials of advanced liver cancerAt present, Deqi Pharma is carrying out clinical development of ATG-008 as a single-drug therapy and combination therapy for the treatment of a wide range of solid tumorsATG-008 completed 452 trials in the United States and the European Union, and Phase 2 clinical trial data show that ATG-008, as the second generation of mTOR dual-target inhibitors, has its unique advantages in terms of safety, tolerance and effectiveness In particular, for patients with advanced liver cancer caused by HBV-plus (hepatitis B virus), the median survival was extended from 5.3 months to more than 12 months after the failure of solafini or chemotherapy, showing significant efficacy in HBV-plus subjects